Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin

Phytochemical‐mediated modulation of cytochrome P450 enzymes (CYPs) may underlie many herb‐drug interactions. This study's purpose was to assess the effects of milk thistle and black cohosh supplementation on CYP3A activity and compare them to a clinically recognized inducer, rifampin, and inhibitor, clarithromycin. Healthy volunteers were randomly assigned to receive a standardized milk thistle (900 mg) or black cohosh (80 mg) supplement for 14 days. Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively. Midazolam was administered orally before and after each supplementation and control period. The effects of milk thistle, black cohosh, rifampin, and clarithromycin on midazolam pharmacokinetics were determined using noncompartmental techniques. Unlike those observed for rifampin and clarithromycin, midazolam pharmacokinetics was unaffected by milk thistle or black cohosh. Milk thistle and black cohosh appear to have no clinically relevant effect on CYP3A activity in vivo.

[1]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[2]  J. Donovan,et al.  Multiple-Dose Administration of Ginkgo biloba Did Not Affect Cytochrome P-450 2D6 or 3A4 Activity in Normal Volunteers , 2003, Journal of clinical psychopharmacology.

[3]  P. Meier,et al.  St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4 , 2000, Clinical pharmacology and therapeutics.

[4]  G. Anderson,et al.  Drug Interaction Potential of Soy Extract and Panax Ginseng , 2003, Journal of clinical pharmacology.

[5]  G. Basso,et al.  Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin. , 1998, Arzneimittel-Forschung.

[6]  R. V. van Breemen,et al.  In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (black cohosh). , 2003, Chemical research in toxicology.

[7]  Feng-qian Li,et al.  Improvement of the dissolution rate of silymarin by means of solid dispersions. , 2004, Chemical & pharmaceutical bulletin.

[8]  J. Schwabe,et al.  St John's wort, a herbal antidepressant, activates the steroid X receptor. , 2000, The Journal of endocrinology.

[9]  P. Kidd,et al.  A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). , 2005, Alternative medicine review : a journal of clinical therapeutic.

[10]  K. Rajnarayana,et al.  Study on the Influence of Silymarin Pretreatment on Metabolism and Disposition of Metronidazole , 2004, Arzneimittelforschung.

[11]  K. Wilson,et al.  Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis , 2005, European Journal of Clinical Pharmacology.

[12]  D. Carrier,et al.  Extraction of nutraceuticals from milk thistle , 2003, Applied biochemistry and biotechnology.

[13]  J. Raucy.  Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[14]  T. Goosen,et al.  Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[16]  U. Fuhr,et al.  Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. , 2000, Pharmacology & toxicology.

[17]  O. Katare,et al.  Formulation, Characterization, and In Vitro Evaluation of Silymarin-Loaded Lipid Microspheres , 2004, Drug delivery.

[18]  J. Falloon,et al.  The effect of garlic supplements on the pharmacokinetics of saquinavir. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Ernst,et al.  Pharmacological effects of Cimicifuga racemosa. , 2003, Life sciences.

[20]  M. Gershwin,et al.  Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. , 1999, Life sciences.

[21]  D. Carrier,et al.  Extraction of nutraceuticals from milk thistle , 2003, Applied biochemistry and biotechnology.

[22]  Kelly H. Jordan,et al.  Coadministration of Milk Thistle and Indinavir in Healthy Subjects , 2003, Pharmacotherapy.

[23]  S. Gardner,et al.  Cytochrome P450 phenotypic ratios for predicting herb‐drug interactions in humans , 2002, Clinical pharmacology and therapeutics.

[24]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[25]  J. Donovan,et al.  Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers , 2003, Clinical pharmacology and therapeutics.

[26]  I. Khan,et al.  Separation ofCimicifuga racemosa triterpene glycosides by reversed phase high performance liquid chromatography and evaporative light scattering detection , 2000 .

[27]  J. Arnason,et al.  In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[28]  J. Strandell,et al.  An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. , 2004, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[29]  J. Falloon,et al.  Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers , 2002, Pharmacotherapy.

[30]  Wei Duan,et al.  Herb-drug interactions: a literature review. , 2005, Drugs.

[31]  Shiew-Mei Huang,et al.  The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo , 2004, Clinical pharmacology and therapeutics.

[32]  P. Woster,et al.  Bergamottin contribution to the grapefruit juice–felodipine interaction and disposition in humans , 2004, Clinical pharmacology and therapeutics.

[33]  A. Fujimura,et al.  Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin , 2001, Clinical pharmacology and therapeutics.

[34]  Disease Prevention.  Complementary and Alternative Medicine in the United States , 2005 .

[35]  S. Strom,et al.  Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[36]  S. Gardner,et al.  Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly , 2005, Drugs & aging.

[37]  E. Perucca,et al.  Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. , 1992, Arzneimittel-Forschung.

[38]  K. Bachmann.  Genotyping and Phenotyping the Cytochrome P-450 Enzymes , 2002, American journal of therapeutics.

[39]  Z. Dvořák,et al.  Effect of Silybin and its congeners on human liver microsomal cytochrome P450 activities , 2002, Phytotherapy research : PTR.

[40]  E. Ernst,et al.  Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. , 1998, British journal of clinical pharmacology.

[41]  E. Perucca,et al.  Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. , 1994, International journal of clinical pharmacology and therapeutics.

[42]  J. Gorski,et al.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.

[43]  Ying Ruan,et al.  Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[44]  M. Waye,et al.  Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. , 2004, Pharmacogenetics.

[45]  M. Harkey,et al.  Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. , 1999, Life sciences.

[46]  E. Choo,et al.  Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects , 2002, Journal of clinical pharmacology.

[47]  S. Tsukamoto,et al.  Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa) , 2005, Evidence-based complementary and alternative medicine : eCAM.

[48]  S. Scheitel,et al.  Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. , 1999, Mayo Clinic proceedings.

[49]  E. D. Lee,et al.  Comparative bioavailability of silibinin in healthy male volunteers. , 2003, International journal of clinical pharmacology and therapeutics.

[50]  I. Khan,et al.  In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto , 2004, Clinical pharmacology and therapeutics.

[51]  W. Ambrosius,et al.  The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity , 2003, Clinical pharmacology and therapeutics.

[52]  H. Kroemer,et al.  Use of Probe Drugs as Predictors of Drug Metabolism in Humans , 1997, Journal of clinical pharmacology.

[53]  I. Khan,et al.  In Vivo Effects of Goldenseal, Kava Kava, Black Cohosh, and Valerian on Human Cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 Phenotypes , 2005, Clinical pharmacology and therapeutics.

[54]  R. Kim,et al.  Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects , 2003, Clinical pharmacology and therapeutics.

[55]  M. Levine,et al.  Drug-Herb Interaction Among Commonly Used Conventional Medicines: A Compendium for Health Care Professionals , 2003, American journal of therapeutics.